Another study in patients with moderate to severe idiopathic PAH indicated that treatment with bosentan diminuted the expression of pro-inflammatory biomarkers such as ICAM-1, VCAM-1, IL-6 along with BNP and ameliorated the clinical status of the patients [256]. Here, ICAM1 is linked to pulmonary arterial hypertension.